Editas Medicine (NASDAQ:EDIT – Get Free Report) and GRI Bio (NASDAQ:GRI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.
Volatility and Risk
Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.38, meaning that its stock price is 238% less volatile than the S&P 500.
Profitability
This table compares Editas Medicine and GRI Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Editas Medicine | -430.84% | -277.29% | -62.49% |
| GRI Bio | N/A | -381.74% | -206.45% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Editas Medicine | 1 | 1 | 2 | 2 | 2.83 |
| GRI Bio | 1 | 0 | 2 | 0 | 2.33 |
Editas Medicine presently has a consensus target price of $5.00, indicating a potential upside of 150.00%. GRI Bio has a consensus target price of $644.00, indicating a potential upside of 24,958.37%. Given GRI Bio’s higher probable upside, analysts clearly believe GRI Bio is more favorable than Editas Medicine.
Insider & Institutional Ownership
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 2.1% of Editas Medicine shares are held by insiders. Comparatively, 8.7% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Editas Medicine and GRI Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Editas Medicine | $32.31 million | 6.04 | -$237.09 million | ($2.38) | -0.84 |
| GRI Bio | N/A | N/A | -$11.96 million | ($235.02) | -0.01 |
GRI Bio has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Editas Medicine beats GRI Bio on 8 of the 13 factors compared between the two stocks.
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
About GRI Bio
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
